Claiming that Europe was "stuck in a bad place", because of the macro-economic issues it faces, GlaxoSmithKline PLC's CEO Andrew Witty believes the U.S. and Japan are currently the world's "core innovation markets.”
Although GSK will still develop products for Europe, the priority going forward would be to design them for other markets,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?